BRKRPHIGH SIGNALFINANCIAL10-K

Revenue surged 306% to $1.9B while the company swung from $113M profit to an $8.6M loss, indicating potential acquisition activity or significant operational challenges.

The massive revenue increase combined with profitability deterioration suggests either a major acquisition that hasn't yet achieved operational synergies, or serious margin compression issues. The addition of Series A preferred stock language and detailed segment restructuring descriptions support an acquisition hypothesis, though investors should be concerned about the dramatic profit decline despite revenue growth.

Comparing 2026-02-27 vs 2025-03-03View on EDGAR →
FINANCIAL ANALYSIS

BRKRP experienced explosive revenue growth of 306% to $1.9B, but this came at a severe cost as the company swung from $113M net income to an $8.6M loss and operating income plummeted 73% to $68.2M. While the balance sheet strengthened with cash increasing 63% to $299M, debt declining 11%, and equity growing 38% to $2.5B, operating cash flow declined 46% to $134M, suggesting the revenue growth may not be translating to sustainable cash generation. This pattern strongly indicates major acquisition activity where integration costs and one-time expenses are overwhelming the financial benefits in the near term.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
+306.3%
$466.6M$1.9B

Strong top-line growth of 306.3% — accelerating demand or successful expansion into new markets.

Net Income
P&L
-107.6%
$113.1M-$8.6M

Net income declined 107.6% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-73.1%
$253.1M$68.2M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Cash & Equivalents
Balance Sheet
+62.9%
$183.4M$298.8M

Cash position surged 62.9% — strong cash generation or capital raise providing significant financial cushion.

Operating Cash Flow
Cash Flow
-46.6%
$251.3M$134.1M

Operating cash flow fell 46.6% — earnings quality concerns; investigate working capital changes and non-cash items.

Stockholders Equity
Balance Sheet
+37.9%
$1.8B$2.5B

Equity base grew 37.9% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Capital Expenditure
Cash Flow
-21.2%
$115.3M$90.8M

Capex reduced 21.2% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Total Debt
Balance Sheet
-10.8%
$2.1B$1.9B

Debt reduced 10.8% — deleveraging strengthens balance sheet and reduces financial risk.

LANGUAGE CHANGES
NEW — 2026-02-27
PRIOR — 2025-03-03
ADDED
As of February 20, 2026, there were 152,219,250 of the registrant s common stock outstanding and 2,760,000 of the registrant s Series A mandatory convertible preferred stock outstanding.
Business Segments We have four reportable segments, Bruker Scientific Instruments ( BSI ) BioSpin, BSI CALID (Chemicals, Applied Markets, Life Science, In Vitro Diagnostics, Detection), BSI NANO, and Bruker Energy Supercon Technologies ( BEST ), which each comprise several divisions as disclosed below.
It offers comprehensive software solutions for workflow integration, automation, and artificial intelligence readiness, adhering to Findability, Accessibility, Interoperability, and Reusability ( FAIR ) data principles.
During 2025, we continued our focus on enhancing customer relationships and driving innovation with our key initiatives, which include expanding into high-potential markets, leveraging core strengths, and driving recurring revenue through aftermarket and connected services.
Furthermore, during 2025, we completed certain minority investments which align with the segment s goals of expanding its technological capabilities, entering new markets, and enhancing its product portfolio.
+7 more — sign up free →
REMOVED
Our principal executive offices are located at 40 Manning Road, Billerica, MA 01821, and our telephone number is (978) 663-3660.
Business Segments We have four reportable segments, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID (Chemicals, Applied Markets, Life Science, In Vitro Diagnostics, Detection), BSI NANO, and Bruker Energy Supercon Technologies (BEST).
Furthermore, BSI BioSpin s product enables the characterization of mixtures and also complex materials, rendering them high value-added tools for a variety of industrial applications.
It offers comprehensive software solutions for workflow integration, automation, and artificial intelligence readiness, adhering to Findability, Accessibility, Interoperability, and Reusability (FAIR) data principles.
Automation: Provides solutions for lab automation and digitalization in Research Development and Quality Control.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →